TrialHematological oncology2009

Phase II study of arsenic trioxide and ascorbic acid for relapsed or refractory lymphoid malignancies: a Wisconsin Oncology Network study.

J E Chang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.